🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published in nature! nature.com/articles/s4158…

🧬In MIBC, deleterious DDR gene alterations, especially ERCC2, show promise as markers for better response to cisplatin-based chemotherapy. 🧬Patients with these alterations had higher rates of pathologic response, suggesting the potential for personalized NAC strategies in

Join us for the GUARD Symposium🇪🇸 featuring interactive workshops where experts collaboratively discuss real-world genitourinary cancer cases. REGISTER👉 events.tacticsmd.net/guard-internat… ⭐️FREE VIRTUAL Admission for LMIC's & LATAM Colleagues⭐️ Here is our Colleague Dr. Felipe Couñago PhD🇪🇸 with

It was great to attend ASCO2025 in Chicago.Some exciting &practice changing data was presented. Highlight was to connect with so many of my friends. Our ongoing trial NEOWIN was presented as well. ⁦Enrique Grande⁩ ⁦Andrea Necchi⁩ ⁦Yoan Loriot⁩ ⁦ASCO⁩

Few more highlights

Join us for the GUARD Symposium🇪🇸 featuring interactive workshops where experts collaboratively discuss real-world genitourinary cancer cases. REGISTER👉 events.tacticsmd.net/guard-internat… ⭐️FREE VIRTUAL Admission for LMIC's & LATAM Colleagues⭐️ Here is our Colleague Dr. Ainara Azueta🇪🇸

Day One 🚨 #GUARDSymposium2025 AI in diagnostic imaging being presented by Dr. Almudena Fuster AI is revolutionizing genitourinary oncology diagnostics by overcoming the limitations of traditional imaging. Radiomics, a key AI application, extracts valuable quantitative data

🌟🔵 Redefining metastatic hormone-sensitive prostate cancer Javier Puente OncoAlert #GUARDSymposium2025 🔹 Timing & burden define prognosis in mHSPC 🔹 Drug selection = disease + patient + regimen factors 🔹 Triplet therapy: 94% support in high-volume, fit patients 🔹 APCCC vote:

A GREAT DAY TWO of #GUARDSymposium2025 JOIN US TODAY FOR THIS FINAL DAY REGISTER👉 buff.ly/r4vwa6B STILL NOT TOO LATE TO JOIN US VIRTUALLY!!! ⭐️FREE VIRTUAL Admission for LMIC's & LATAM Colleagues⭐️ Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos

🌟🔵 Rethinking high-risk NMIBC: from BCG to future paradigms Félix Guerrero-Ramos OncoAlert #GUARDSymposium2025 A powerful session bridging evidence & real-world barriers 🔹 BCG works → still cornerstone therapy (solo or in combo) 🔹 CREST: BCG + systemic chemo ↓ CIS & high-grade

🌟🔵 Perioperative IO in MIBC: where are we heading? Presentation by Dr. Andrea Necchi #GUARDSymposium2025 OncoAlert Advanced Prostate Cancer Consensus Conference 🌟Critical questions remain: pCR utility, timing, IO-only options 🔹 Neoadjuvant: better compliance, early systemic control & biomarker discovery

🌟🟠 Bladder Sparing in MIBC Presented by Matt Galsky @MountSinaiCancer OncoAlert @GUARDConsortium #GUARDSymposium2025 👀 Patient selection is key. Should all that can be done actually be done? 🔵 TURBT + systemic tx remains limited by historical barriers: lack of biomarkers,

LIVE Day TWO #GUARDSymposium2025 Presentation by Dr. Matt Galsky🇺🇸 How to select patients in whom we preserve the bladder without local treatment? Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido Javier Molina Cerrillo David Lorente

It was my pleasure to contribute and present at the exciting GUARD symposium. Delighted 2 see its growth &new research developed under its wings. Tom Powles Matt Galsky Andrea Necchi Roberto Iacovelli jim catto Daniel Castellano Enrique Grande Félix Guerrero-Ramos 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Yüksel Ürün

Day TWO #GUARDSymposium2025 🚨 Presentation by Syed A Hussain One line, several options: individualization of treatment in first-line metastatic #BladderCancer Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido

Durvalumab approved in the 🇪🇺EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer. Based on NIAGARA trial: 32% ⬇️recurrence risk, 25%⬇️ risk of death. Proud to be part of this journey as a study site. OncoAlert World Bladder Cancer Patient Coalition Tom Powles

U.S. FDA approves durvalumab for perioperative immunotherapy for patients with muscle-invasive bladder cancer In a prespecified analysis, the trial demonstrated a statistically significant improvement in event-free survival and overall survival. American Cancer Society Suresh S. Ramalingam, MD, FASCO

Thank you for visiting us Kari Tikkinen Great minds, great energy, more than happy to collaborate. Let’s build new ideas together! Ankara Üniversitesi European Association of Urology (EAU) Cagri Akpinar, MD, FEBU

Yüksel Ürün Ankara Üniversitesi European Association of Urology (EAU) Cagri Akpinar, MD, FEBU Syed A Hussain Maria J. Ribal jim catto Enrique Grande Gianluca Giannarini Alberto Briganti Axel S. Merseburger Emre Yekedüz Ilker Tinay Kate Sears Thank you so much Yüksel Ürün Ankara Üniversitesi for the kind words and warm welcome! Great to exchange ideas and explore future collaborations! Looking forward to what we can achieve together. European Association of Urology (EAU) University of Helsinki Syed A Hussain jim catto

Great to see the international collaborations moving the field forward and answering questions within randomised trials to further improve clinical outcome & QOL gains for our patients globally. Kari Tikkinen Yüksel Ürün jim catto Enrique Grande ASCO The University of Sheffield Daniel Castellano